Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
109
datasets available to search
ShareScore release 0.7.1
Dataset results
109 results for “Covid-19 mortality”
Predictive Value of SOFA and APACHE Scores for In-hospital Mortality in COVID-19 ICU Patients
ClinicalTrials.gov study NCT04713852. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Air temperature influences early Covid-19 outbreak as indicated by worldwide mortality
Open the record for dataset details and reuse information.
Data from: Clinical management and mortality among COVID-19 cases in sub-Saharan Africa: a retrospective study from Burkina Faso and simulated case analysis.
Open the record for dataset details and reuse information.
Data from: The association of county-level presidential election outcome and COVID-19 mortality in Colorado, 2020-2022
Open the record for dataset details and reuse information.
Neutrophil-mediated oxidative stress and albumin structural damage predict COVID-19-associated mortality
Open the record for dataset details and reuse information.
Development and validation of a machine learning model for use as an automated artificial intelligence tool to predict mortality risk in patients with COVID-19
<p><strong>Background</strong></p> <p>New York City quickly became an epicenter of the COVID-19 pandemic. Due to a sudden and massive increase in patients during COVID-19 pandemic, healthcare providers incurred an exponential increase in workload which created a strain on the staff and limited resources. As this is a new infection, predictors of morbidity and mortality are not well characterized.</p> <p><strong>Methods</strong></p> <p>We developed a prediction model to predict patients at risk for mortality using only laboratory, vital and demographic information readily available in the electronic health record on more than 3000 hospital admissions with COVID-19. A variable importance algorithm was used for interpretability and understanding of performance and predictors.</p> <p><strong>Findings</strong></p> <p>We built a model with 84-97% accuracy to identify predictors and patients with high risk of mortality, and developed an automated artificial intelligence (AI) notification tool that does not require manual calculation by the busy clinician. Oximetry, respirations, blood urea nitrogen, lymphocyte percent, calcium, troponin and neutrophil percentage were important features and key ranges were identified that contributed to a 50% increase in patients’ mortality prediction score. With an increasing negative predictive value (NPV) starting 0.90 after the second day of admission, we are able more confidently able identify likely survivors. This study serves as a use case of a model with visualizations to aide clinicians with a better understanding of the model and predictors of mortality. Additionally, an example of the operationalization of the model via an AI notification tool is illustrated.</p>
Serum 25(OH)D level on hospital admission is correlated with COVID-19 mortality
<p>Objective: Vitamin D deficiency was previously correlated with incidence and severity of COVID-19. We investigated the correlation between serum 25(OH)D level on admission and radiological stage and outcome of COVID-19 pneumonia. </p> <p>Methods: Retrospective observational trial on 186 SARS-CoV-2-infected individuals hospitalized from March 1, 2020 to April 7, 2020 with combined chest CT and 25(OH)D measurement on admission. Multivariate analysis was performed to study if vitamin D deficiency (25(OH)D < 20 ng/mL) predicts survival independently of confounding comorbidities. </p> <p>Results: 59% of COVID-19 patients were vitamin D deficient on admission: 47% of females and 67% of males. Particularly male COVID-19 patients showed progressively lower 25(OH)D with advancing radiological stage, with deficiency rates increasing from 55% in stage 1 to 74% in stage 3. Vitamin D deficiency on admission was not confounded by age, chronic lung disease, coronary artery disease/hypertension or diabetes and was correlated with mortality (OR=3.87, 95%CI 1.30-11.55), independently of other predictors including age (OR=1.09, 95%CI 1.03-1.14), chronic lung disease (OR=3.61, 95% CI 1.18-11.09) and extent of lung damage expressed by chest CT severity score (1.12, 95% CI 1.01-1.25). </p> <p>Conclusions: low 25(OH)D levels on admission are associated with COVID-19 disease mortality</p>
COVID-19 Mortality Risk Assessment Among Various Age Groups Using Phylogenetic Analysis
<p>The datasets used for the analysis titled <strong>Phylogenomic analysis of all available COVID-19 genomes and its influence on mortality</strong></p>
Systemic corticosteroids and mortality in severe and critical COVID-19 patients in Wuhan, China
<p><strong>Background:</strong> Systemic corticosteroids are now recommended in many treatment guidelines, though supporting evidence is limited to one randomised controlled clinical trial (RECOVERY). </p> <p><strong>Objective:</strong> To identify whether corticosteroids were beneficial to COVID-19 patients. </p> <p><strong>Methods:</strong> 1514 severe and 249 critical hospitalized COVID-19 patients from two medical centers in Wuhan, China. Multivariable Cox models, Cox model with time-varying exposure and propensity score analysis (inverse-probability-of-treatment-weighting (IPTW) and propensity score matching (PSM)) to estimate the association of corticosteroid use with risk of in-hospital mortality in severe and critical cases.</p> <p><strong>Results:</strong> Corticosteroids were administered in 531 (35.1%) severe and 159 (63.9%) critical patients. Compared to non-corticosteroid group, systemic corticosteroid use was not associated with beneficial effect in reducing in-hospital mortality in both severe cases (HR=1.77, 95% CI: 1.08-2.89, p=0.023), and critical cases (HR=2.07, 95% CI: 1.08-3.98, p=0.028). Findings were similar in time-varying Cox analysis. For severe COVID-19 patients at admission, corticosteroid use was not associated with improved or harmful outcome in either PSM or IPTW analysis. For critical COVID-19 patients at admission, results were consistent with multivariable Cox model analysis.</p> <p><strong>Conclusion:</strong> Corticosteroid use was not associated with beneficial effect in reducing in-hospital mortality for severe or critical cases in Wuhan. Absence of the beneficial effect in our study in contrast to that was observed in the RECOVERY clinical trial may be due to biases in observational data, in particular prescription by indication bias, differences in clinical characteristics of patients, choice of corticosteroid used, timing of initiation of treatment and duration of treatment. <br> </p>
Factors associated with COVID-19 infections and mortality in Africa: A cross-sectional study using publicly available data
<p><span><b>Introduction</b></span></p> <p><span>The current COVID-19 pandemic is a global threat. This elicits questions on the level of preparedness and capacity of health systems to respond to emergencies. Relative to other parts of the world, Africa has poorly developed health systems with limited capacity to respond to health crises. Africa is particularly disadvantaged.</span></p> <p><span><b>Methods</b></span></p> <p><span>This cross-sectional study uses publicly available core health data for 53 African countries, to determine risk factors for cumulative COVID-19 deaths and cases per million in all countries in the continent. Descriptive statistics were determined for the indicators and a negative binomial regression was used for modelling the risk factors.</span></p> <p><span><b>Results</b></span></p> <p><span>In Sub-Saharan Africa, an increase in the number of nursing and midwifery personnel decreased the risk of COVID-19 deaths (p=0.0178) while a unit increase in UHC index of service coverage and prevalence of insufficient physical activity among adults increased the risk of COVID-19 deaths (p=0.0432 and p=0.0127). An increase in the proportion of infants initiating breastfeeding reduced the number of cases per million (p<0.0001) while an increase in higher healthy life expectancy at birth increased the number of cases per million (p=0.0340).</span></p> <p><span><b>Conclusion</b></span></p> <p><span>Despite its limited resources, Africa's preparedness and response to the COVID-19 pandemic can be improved by identifying and addressing <i>specific</i> gaps in the funding of health services delivery. These gaps impact negatively on service delivery but appear to have received limited funding and policy priority. </span></p>
Supplementary Table 1 of the Schöley et al. Lancet correspondence on "Conflicting COVID-19 excess mortality estimates"
<p>See https://github.com/jschoeley/ihme_excess_validation for the code re-creating the published figure from the supplementary table 1.</p>
Physical Activity and the Risk of COVID-19 Infection and Mortality
ClinicalTrials.gov study NCT04631861. IPD Sharing: NO. Countries: 0. Publications: 4.
Serum 25(OH)D level on hospital admission is correlated with COVID-19 mortality
Open the record for dataset details and reuse information.
Factors associated with COVID-19 infections and mortality in Africa: A cross-sectional study using publicly available data
Open the record for dataset details and reuse information.
Systemic corticosteroids and mortality in severe and critical COVID-19 patients in Wuhan, China
Open the record for dataset details and reuse information.
TET2 Mutant Clonal Hematopoiesis Enhances Severity of COVID-19 Related Cytokine Release Syndrome and is Associated with Increased Mortality [scMULT]
GEO Series GSE210432. Homo sapiens. 36 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
TET2 Mutant Clonal Hematopoiesis Enhances Severity of COVID-19 Related Cytokine Release Syndrome and is Associated with Increased Mortality.
GEO Series GSE210435. Homo sapiens. 363 samples. Type: Methylation profiling by genome tiling array; Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing; Other.
TET2 Mutant Clonal Hematopoiesis Enhances Severity of COVID-19 Related Cytokine Release Syndrome and is Associated with Increased Mortality [scRNA-seq]
GEO Series GSE210433. Homo sapiens. 34 samples. Type: Expression profiling by high throughput sequencing.
Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients
<p><strong>Background: </strong>Imatinib reduced 90-day mortality in hospitalised coronavirus disease 2019 (COVID-19) patients in a recent clinical trial, but the biological effects that cause improved clinical outcomes are unknown. We aimed to determine the biological changes elicited by imatinib in patients with COVID-19 and what baseline biological profile moderates the effect of imatinib.</p> <p><strong>Methods:</strong> We undertook a secondary analysis of a randomised, double-blind, placebo-controlled trial of oral imatinib in hospitalised, hypoxaemic COVID-19 patients. Mediating effects of changes in plasma concentration of 25 plasma host response biomarkers on the association between randomisation group and 90-day mortality were studied by combining linear mixed effect modelling and joint modelling. Moderation of baseline biomarker concentrations was evaluated by Cox regression modelling. We identified subphenotypes using Ward’s method clustering and evaluated moderation of these subphenotypes using the aforementioned method.</p> <p><strong>Results:</strong> 332 out of 385 participants had plasma samples available. Imatinib increased the concentration of surfactant protein D (SP-D), and decreased the concentration of interleukin-6, procalcitonin, angiopoietin (Ang)-2/Ang-1 ratio, E-selectin, tumour necrosis factor (TNF)-α, and TNF receptor I. The effect of imatinib on 90-day mortality was fully mediated by changes in these biomarkers. Cluster analysis revealed three host response subphenotypes. Mortality benefit of imatinib was only present in the subphenotype characterised by alveolar epithelial injury indicated by increased SP-D levels in the context of systemic inflammation and endothelial dysfunction (hazard ratio 0.30, 95% CI 0.10–0.92).</p> <p><strong>Conclusions: </strong>The effect of imatinib on mortality in hospitalised COVID-19 patients is mediated through modulation of innate immune responses and reversal of endothelial dysfunction, and possibly moderated by biological subphenotypes.</p>
Dexamethasone and COVID-19 Inpatient Mortality
ClinicalTrials.gov study NCT04926571. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.